PDCD1 and neoplasm: Several recent studies demonstrate that human CXCL13+CD4+ and CXCL13+CD8+ T cells, which are also phenotypically similar to exhausted or hyperactivated T cells, are tumor antigen–specific and mediate responses to the anti-PD-1 therapy (9, 30–34).